Dock-and-Lock Antibody Complexes for B-Cell Lymphoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies with monoclonal antibodies face challenges such as immunogenicity and suboptimal pharmacokinetics, and there is a need for more effective combination therapies to address signaling pathway redundancies and enhance antitumor activity.
Innovation Solution
The development of combination therapy using a trivalent, tetravalent, or hexavalent construct made by the dock-and-lock (DNL) technique, which combines anti-CD74 antibodies or fragments with other therapeutic agents like anti-CD20 or anti-CD22 antibodies, forming stable complexes that retain binding specificity and affinity, enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combination therapy with multiple antibodies is used, then therapeutic efficacy is improved, but device complexity increases
Solution Approach 1:
The patent combines multiple antibody specificities (anti-CD74 and anti-CD20) into a single bispecific antibody construct using the dock-and-lock technique. This merging approach allows the molecule to simultaneously engage both CD74 and CD20 antigens, providing synergistic therapeutic effects while simplifying the treatment regimen compared to administering separate antibodies.
Solution Approach 2:
The bispecific antibody construct performs multiple functions: it binds to CD74 on B-cell lymphoma cells, binds to CD20 on the same or different cells, and can recruit immune effectors through Fc region interactions. This multi-functionality allows a single molecule to accomplish what would otherwise require multiple separate therapeutic agents.
2Ease of operation
If monoclonal antibody therapy is used, then treatment is simplified, but immunogenicity and suboptimal pharmacokinetics occur
Solution Approach 1:
The patent employs a composite antibody structure that combines human constant regions with variable regions targeting different antigens. This composite design improves pharmacokinetics by utilizing human Fc regions that are less immunogenic and have optimized serum half-life, while maintaining the ability to bind multiple human antigens (CD74 and CD20) with high specificity.
3Ease of operation
If single-agent antibody therapy is used, then treatment protocol is simple, but signaling pathway redundancies reduce effectiveness
Solution Approach 1:
The bisspecific antibody construct merges the functionality of targeting CD74 and CD20 into a single therapeutic agent. This allows simultaneous disruption of multiple signaling pathways and antigen expressions that B-cell lymphoma cells use for survival and proliferation, overcoming the redundancy problem that limits single-agent therapies.
Data Source
AI summary
Disclosed are compositions and methods comprising combinations of anti-CD74 and anti-CD20 antibodies or antigen-binding fragments thereof. The antibody combination may also be used with a therapeutic agent that is attached to antibody or fragment thereof or separately administered. The therapeutic agent may be an immunomodulator, a cytokine, a toxin or other known therapeutic agent. Preferably, the anti-CD74 and anti-CD20 antibody or fragment are part of a DNL complex. More preferably, combination therapy with the anti-CD74 and anti-CD20 antibody or fragment is more effective than either antibody alone, or the combination of unconjugated antibodies. Administration of combination induces apoptosis of target cells in diseases in which CD74 is overexpressed, such as solid tumors, B-cell lymphomas or leukemias, autoimmune disease, immune dysfunction disease or diabetes. Preferably, the target cells are B cells.